Clinical Trials
13
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (13 trials with phase data)• Click on a phase to view related trials
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
- Conditions
- Non-Alcoholic Fatty Liver Disease
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2024-11-26
- Lead Sponsor
- Valbiotis
- Target Recruit Count
- 70
- Registration Number
- NCT06704321
- Locations
- 🇨🇦
Institut sur la nutrition et les aliments fonctionnels (INAF), Québec, Quebec, Canada
Effect of the Food Supplement TOTUM-070 on Lipid Metabolism
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2024-02-06
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Valbiotis
- Target Recruit Count
- 180
- Registration Number
- NCT06243484
- Locations
- 🇩🇪
Biotesys, Esslingen, Germany
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
- Conditions
- Mild Inflammatory ContextNAFLDMASLD
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Valbiotis
- Target Recruit Count
- 10
- Registration Number
- NCT06047847
- Locations
- 🇫🇷
University Hospital Clermont-Ferrand, Clermont-Ferrand, France
Effects of 6 Weeks TOTUM-070 on Lipid Metabolism and Cardiovascular Health in Individuals at Increased Cardio-metabolic Risk
- Conditions
- HypercholesterolemiaCardiovascular Risk FactorDyslipidemiasAtherosclerosisCardio-metabolic Risk
- First Posted Date
- 2022-10-26
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Valbiotis
- Target Recruit Count
- 31
- Registration Number
- NCT05594979
- Locations
- 🇫🇷
CIC Clermont Ferrand, Clermont-Ferrand, France
Effect of TOTUM-854 on Blood Pressure in Subjects With Moderately Elevated Blood Pressure
- Conditions
- Metabolic SyndromePrehypertensionElevated Blood PressureBlood Pressure
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Valbiotis
- Target Recruit Count
- 410
- Registration Number
- NCT05469503
- Locations
- 🇧🇬
Multiprofile Hospital for Active Treatment Cardiology Department, Haskovo, Bulgaria
🇧🇬Multiprofile Hospital for Active Treatment - Uni Hospital OOD, Cardiology Department, Panagyurishte, Bulgaria
🇧🇬Diagnostic Consultative Center VII-Plovdiv South district EOOD, Cabinet of Endocrinology, Plovdiv, Bulgaria
- Prev
- 1
- 2
- 3
- Next
News
Valbiotis' Lipridrive Demonstrates Efficacy in Phase II/III Trial for Hypercholesterolemia
Valbiotis' Lipridrive met its primary endpoint in a Phase II/III trial, significantly reducing LDL cholesterol in patients with mild to moderate hypercholesterolemia.